胸腺组织比例预测局部晚期NSCLC放射性肺炎
本研究在RTOG 0617(n=453)和MSKCC(n=230)两个队列中,评估CT衍生的胸腺组织百分比(pTT)与局部晚期NSCLC同步放化疗后高级别放射性肺炎的关联。结果显示高pTT与较低的重度肺炎发生率独立相关,低pTT且高肺V20患者风险最高,提示pTT可作为宿主特异性影像生物标志物用于风险分层。
要点
- 高pTT与重度肺炎风险降低独立相关,不受肺V20影响。
- 低pTT且高肺V20患者发生重度肺炎的风险最高。
- 胸腺区域平均辐射剂量与肺炎风险呈较弱的非线性关系。
核心结论
- pTT是一种可解释的宿主特异性影像生物标志物,与局部晚期NSCLC同步放化疗后重度肺炎相关。
- 将pTT纳入风险分层可能改善个体化治疗计划并支持更安全地实施根治性治疗。
研究设计与样本
- 回顾性分析RTOG 0617试验中接受同步放化疗(联合或不联合度伐利尤单抗)的局部晚期NSCLC患者453例。
- 回顾性分析MSKCC单中心接受同步放化疗(联合或不联合度伐利尤单抗)的局部晚期NSCLC患者230例。
- pTT通过自动分割和高斯混合模型从治疗前CT中提取。
- 采用限制性立方样条逻辑回归评估pTT、胸腺区域平均辐射剂量和肺V20与高级别(≥3级)肺炎的关联。
主要发现
- RTOG 0617队列中,低pTT患者3级及以上肺炎发生率为8.0%,高pTT患者为3.1%(p=0.03)。
- MSKCC队列中,低pTT患者3级及以上肺炎发生率为13.9%,高pTT患者为5.2%(p=0.04)。
- 高pTT与较低的重度肺炎发生率相关,且独立于肺V20。
- 低pTT且高肺V20的患者重度肺炎发生率最高。
- 胸腺区域平均辐射剂量与肺炎风险呈较弱的非线性关系。
临床怎么用
- 可利用治疗前CT自动提取pTT,辅助识别同步放化疗后重度肺炎高风险患者。
- 对低pTT且高肺V20患者应加强肺炎风险监测与个体化治疗计划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Durvalumab consolidation after concurrent chemoradiotherapy (cCRT) is standard for unresectable stage III NSCLC; however, radiation pneumonitis (RP) remains a major treatment-limiting toxicity. Lung dosimetry incompletely explains the risk of toxicity. Recent studies have established radiographic thymic health as clinically relevant in cancer, but its relationship to treatment-related toxicity remains unclear. We evaluated whether percent thymic tissue (pTT), an interpretable CT-derived measure of residual thymic tissue, is associated with severe pneumonitis after cCRT in NSCLC. METHODS: We analyzed patients with locally advanced NSCLC treated with cCRT with or without durvalumab in RTOG 0617 (n = 453) and at the Memorial Sloan Kettering Cancer Center (MSKCC, n = 230). pTT was derived from pretreatment CT using autosegmentation and Gaussian mixture modeling. Logistic regression with restricted cubic splines assessed the associations of pTT, mean radiation dose to the thymic region, and volume of lungs receiving more than or equal to 20 Gy (lung V20) with high-grade (≥3) pneumonitis. RESULTS: Higher pTT was associated with lower severe pneumonitis rates, independent of lung V20. Grade 3+ pneumonitis occurred in 8.0% versus 3.1% of low- versus high-pTT patients in RTOG 0617 (p = 0.03) and in 13.9% versus 5.2% at the MSKCC (p = 0.04). Patients with both low pTT and high lung V20 had the highest severe pneumonitis rates. Mean radiation dose to the thymic region revealed a weaker, nonlinear relationship with pneumonitis risk. CONCLUSIONS: pTT is an interpretable, host-specific radiographic biomarker associated with severe pneumonitis after cCRT in NSCLC. Incorporating pTT into risk stratification may improve individualized treatment planning and support the safer delivery of curative-intent therapy in locally advanced NSCLC.
引用
- Chaunzwa TL, Krishnan G, Book AJ, et al. Thymic Composition Predicts Radiation Pneumonitis in Locally Advanced NSCLC. J Thorac Oncol. 2026. PMID: 42214669. doi:10.1016/j.jtho.2026.103949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。